Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-cash Items (2022 - 2025)

Silence Therapeutics (SLN) has disclosed Non-cash Items for 4 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 109.05% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, up 109.05% year-over-year, with the annual reading at $6.0 million for FY2025, 79.38% down from the prior year.
  • Non-cash Items hit $6.0 million in Q4 2025 for Silence Therapeutics, up from $4.0 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $6.0 million in Q4 2025 to a low of $2.2 million in Q4 2022.
  • Historically, Non-cash Items has averaged $3.6 million across 4 years, with a median of $3.4 million in 2025.
  • Biggest five-year swings in Non-cash Items: decreased 4.47% in 2024 and later surged 109.05% in 2025.
  • Year by year, Non-cash Items stood at $2.2 million in 2022, then surged by 35.56% to $3.0 million in 2023, then fell by 4.47% to $2.9 million in 2024, then skyrocketed by 109.05% to $6.0 million in 2025.
  • Business Quant data shows Non-cash Items for SLN at $6.0 million in Q4 2025, $4.0 million in Q3 2025, and $3.7 million in Q2 2025.